HALO (Halozyme Therapeutics) Other Stockholders Equity: $0 Mil (As of Mar. 2026)


HALO Halozyme Therapeutics Inc HALO
93 GF Score
Price $79.06
GF Value $91.04
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Other Stockholders Equity?

Halozyme Therapeutics HALO -1.61% 93 Other Stockholders Equity is $0 Mil as of Mar. 2026. GuruFocus rates HALO with a GF Score™ of 93/100 and a GF Value™ of $91.04 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Halozyme Therapeutics's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $0 Mil.

Halozyme Therapeutics's quarterly Other Stockholders Equity declined from Sep. 2025 ($0 Mil) to Dec. 2025 ($-0 Mil) but then increased from Dec. 2025 ($-0 Mil) to Mar. 2026 ($0 Mil).

Halozyme Therapeutics's annual Other Stockholders Equity declined from Dec. 2023 ($0 Mil) to Dec. 2024 ($0 Mil) and declined from Dec. 2024 ($0 Mil) to Dec. 2025 ($-0 Mil).

Halozyme Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Other Stockholders Equity Chart

Halozyme Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 -0.00

Halozyme Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00
HALO
93GF Score
Halozyme Therapeutics Inc HALO
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0 Mil mean?
Halozyme Therapeutics (HALO) has a Other Stockholders Equity of $0 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Other Stockholders Equity too high?
Halozyme Therapeutics' current Other Stockholders Equity is $0 Mil. Overall, Halozyme Therapeutics has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Other Stockholders Equity compare to KYMR and IBRX?
Halozyme Therapeutics' Other Stockholders Equity of $0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Other Stockholders Equity is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $91.04, compared to a current price of $79.06 — trading 13.2% below its estimated fair value. The current Other Stockholders Equity is $0 Mil. Halozyme Therapeutics' overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Other Stockholders Equity is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued. The current stock price of $79.06 is trading 13.2% below its estimated GF Value™ of $91.04. GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.

Key valuation signals for HALO:

  • Other Stockholders Equity: $0 Mil
  • GF Value™: $91.04 vs. price of $79.06 (13.2% below fair value)
  • GF Score™: 93/100 with 3 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
93GF Score

Get the complete analysis for HALO

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.06
Price
$91.04
GF Value